CurveBeam AI Completes Partial A$5 Million Placement at $0.02 per Share
CurveBeam AI has secured nearly half of its A$5 million placement at $0.02 per share, issuing 120 million shares to key investors while awaiting the remainder of funds from Intellivision Holdings.
- Partial receipt of A$2.4 million from A$5 million placement
- 120 million shares issued to three investors
- Remaining A$2.6 million funds in transit internationally
- Share issuance contingent on fund receipt
- Upcoming corporate disclosures scheduled early September
Partial Placement Funds Received and Shares Issued
CurveBeam AI Limited (ASX:CVB) has taken a significant step in its capital raising efforts, receiving A$2.4 million of the A$5 million placement approved by shareholders last week. The shares were issued at $0.02 each, reflecting the company’s ongoing strategy to bolster its balance sheet. In total, 120 million shares were allocated today to three investors: Gregory Wayne Brown and Stefanie Brown’s superannuation fund, Arun Singh and Susmita Singh, and Lan Gao.
Remaining Placement Funds Await Clearance
The remaining A$2.6 million from Intellivision Holdings Pte. Ltd. has been remitted but is currently in transit through the international banking system. CurveBeam AI has confirmed that the issuance of the corresponding shares will proceed once these funds clear, introducing an element of timing uncertainty dependent on cross-border settlement processes.
Corporate Reporting and Governance Updates on the Horizon
The company plans to release its Annual Report, Appendix 4G, and Corporate Governance Statement on 31 August 2026, followed by the results of its Share Purchase Plan on 1 September 2026. These disclosures will provide additional insight into CurveBeam AI’s operational and financial position as it navigates the competitive medical imaging market with its AI-enabled CT scanning technology.
Capital Raising in Context of Growth Initiatives
CurveBeam AI’s placement and Share Purchase Plan are part of broader funding efforts to support its specialised CT scanners and AI clinical assessment solutions. The company’s HiRise™ scanner, capable of weight-bearing and traditional CT scans, addresses a niche in musculoskeletal imaging. This capital injection follows recent strategic investments and regulatory progress, positioning CurveBeam AI to advance its product development and market penetration.
Bottom Line?
The completion of the placement’s initial tranche strengthens CurveBeam AI’s cash position, but the timing of the remaining funds and share issuance will be key to watch as the company prepares to report its latest financials.
Questions in the middle?
- When will the remaining A$2.6 million from Intellivision Holdings clear and shares be issued?
- How will the upcoming Annual Report and governance disclosures influence investor sentiment?
- What impact will the capital raise have on CurveBeam AI’s growth plans and regulatory milestones?
